Angiogenesis is fundamentally important to the pathogenesis of clear cell renal cell carcinoma (ccRCC). We investigated the association between variations of genes related to angiogenesis and the risk of ccRCC. In a case-control study of 859 ccRCC patients and 1004 cancer-free subjects, we genotyped 24 potentially functional single nucleotide polymorphisms (SNPs) in seven angiogenesis-related genes (HIF1A, EPAS1, VEGFA, VEGFR1, VEGFR2, VEGFR3 and PDGFRB) using the TaqMan or Snapshot method. Unconditional logistic regression, adjusted for potential confounding factors, was used to assess the risk associations. The functionality of selected SNPs was assessed by real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) and luciferase reporter gene assays. We found two SNPs (VEGFA rs2010963 and VEGFR3 rs448012) that were significantly associated with increased risk of ccRCC, after adjusting for multiple comparisons [rs2010963 CC/GC cf. GG: false discovery rate (FDR) = 0.048, odds ratio (OR) = 1.36, 95% confidence interval (95% CI) = 1.12-1.66; rs448012 CC/GC cf. GG: FDR = 0.048, OR = 1.38, 95% CI =1.13-1.69]. Real-time quantitative PCR revealed that the variant genotypes of rs2010963, but not rs448012, were associated with increased gene expression in normal tissues of ccRCC patients (CC/ GC cf. GG: P = 0.036). The luciferase reporter assay showed that the rs2010963 C allele significantly increased luciferase activity over that of the rs2010963 G allele. Our results indicate that VEGFA rs2010963 and VEGFR3 rs448012 are associated with risk of ccRCC. Furthermore, rs2010963 is a functional SNP that may affect ccRCC susceptibility by modulating endogenous VEGFA expression.
Introduction
Renal cell carcinoma (RCC) is the predominant form of malignancy of the kidney, accounting for >80% of all malignant kidney tumours (1, 2) . The conclusive risk factors identified by epidemiological studies for RCC include tobacco smoking, hypertension and obesity (1) . However, although many people are exposed to these risk factors during their lifetime, only a fraction of them develop RCC. This suggests that genetic susceptibility may be a component of the aetiology of this disease.
Angiogenesis is closely associated with cancer development and progression in various types of tumours (3) (4) (5) . Aberrant angiogenesis is considered a hallmark of RCC, particularly for clear cell renal cell carcinoma (ccRCC), which is a major histologic type of RCC (3) . In the majority of ccRCC cases, the von Hippel-Lindau tumour suppressor gene VHL is functionally disrupted, leading to constitutive activation of hypoxia-inducible factors (HIFs) and subsequent induction of target genes, such as vascular endothelial growth factor (VEGF) (3) .
Genetic variations in angiogenesis-related genes can alter their expression and confer individual susceptibility to tumour (6, 7) . To date, several candidate gene association studies and large genome-wide association studies have indicated that single nucleotide polymorphisms (SNPs) in genes involved in angiogenesis are associated with RCC risk. For example, Ollerenshaw et al. (8) reported that two functional SNPs in hypoxia inducible factor 1 alpha (HIF1A) could confer susceptibility to RCC, and Bruyère et al. (9) suggested that the VEGF genotype polymorphism at position −460 is a risk factor for RCC. Furthermore, the genome-wide association study on RCC conducted by Purdue et al. (10) with a European population identified three loci associated with RCC susceptibility. One of these loci was located in the region of 2p21 (rs11894252 and rs7579899 were correlated variants), which mapped at endothelial PAS domain protein 1 (EPAS1; encoding HIF-2 alpha). However, these findings were not replicated by our previous studies with a Chinese population (11, 12) . This suggests that differences exist in genetic architecture across ethnic groups, and investigations into genetic variations in other candidate genes are still necessary.
We previously found evidence that SNPs in VHL and HIF1A do not influence RCC susceptibility but may jointly influence RCC progression and survival (11) . However, systemic studies on the association between angiogenesis-related genes and the risk of ccRCC are lacking. In the present study, we expanded exploration to a greater number of genes putatively involved in angiogenesis. We reviewed seven core genes [HIF1A, EPAS1, VEGFA, VEGFR1, VEGFR2, VEGFR3 (VEGF receptors 1-3) and PDGFRB (platelet-derived growth factor receptor beta)] and analyzed 24 potentially functional SNPs in these genes for their influence on the prevalence of RCC in a Chinese population.
Patients and methods

Ethics statement
The Institutional Review Board of Nanjing Medical University, Nanjing, China, approved this study. At recruitment, all participants provided written informed consent.
Study subjects
This case-control study comprised 859 ccRCC cases and 1004 cancer-free controls. All subjects were ethnic Han Chinese from different families, with no consanguinity among the participants. All the diagnoses of ccRCC were new and histopathologically confirmed. The ccRCC patients had no history of other cancers or previous chemotherapy or radiotherapy and were consecutively recruited without age or gender restrictions. Each patient's ccRCC was classified and staged according to criteria of the World Health Organization and the tumour-node-metastasis classification of the American Joint Committee on Cancer. The Fuhrman scale was used to assess tumour nuclear grade.
The 1004 controls were recruited from healthy subjects seeking physical examination in the outpatient departments of the hospital and were frequencymatched to the ccRCC cases based on age (±5 years) and gender. After each participant provided written informed consent, each donated 5 ml blood from a peripheral vein.
Selections of SNPs
Seven genes (HIF1A, EPAS1, VEGFA, VEGFR1, VEGFR2, VEGFR3 and PDGFRB) selected in our study are putatively associated with angiogenesis in tumours. According to the CHB (i.e. Han Chinese in Beijing, China) data from HapMap (http://hapmap.ncbi.nlm.nih.gov/), dbSNP (http://www.ncbi. nlm.nih.gov/projects/SNP/) and Haploview software 4.2 (http://www.broadinstitute.org/haploview), several tag-SNPs in these seven genes were selected via a pair-wise tag-SNP algorithm based on correlation coefficient (r 2 ) linkage disequilibrium. The screening criteria were (i) minor allele frequency > 5% in the Chinese population and (ii) r 2 threshold > 0.8. Twenty-four tag-SNPs were identified for further analysis.
DNA extraction and genotyping
Genomic DNA was isolated and purified from the peripheral blood using QIAamp DNA Blood Kit. The selected 24 tag-SNPs were genotyped by SNapShot assay in accordance with the manufacturer's instructions (Applied Biosystems, Foster City, CA). The primers and probes for each tag-SNPs are available upon request. In accordance with the manufacturer's instructions, the reaction was performed in a 40-µl volume containing 2 µl extracted genomic DNA, 1 µl of 50 mM MgCl 2 , 1 µl of 10 mM dNTP, 4 µl of 10× buffer, 1 µl of primer mix and 0.4 µl of 5 U Platinum Taq DNA polymerase in 30 µl of DNasefree water, as follows: 95°C for 2 min and 33 cycles of 94°C for 20 s, 56°C for 30 s and 72°C for 40 s. The polymerase chain reaction (PCR) product was purified using the shrimp alkaline phosphatase (SAP) method, which included 0.3 µl of SAP, 0.2 µl Exonuclease I, 2 µl PCR product and 7.5 µl ddH 2 O, beginning at 37°C for 100 min and then 75°C for 15 min.
The extension reaction was carried out in a 5-µl volume containing 2.5 µl of Reaction Mix (Applied Biosystems), 1 µl Probe Mix and 1.5 µl PCR product and performed in 25 cycles of 96, 51 and 60°C for 10, 5 and 30 s, respectively. The extension products were also purified using the SAP method and analyzed in a 96-well Prism 3730 DNA Sequencer (Applied Biosystems). About 10% of samples were randomly selected for repeated assays, and the results were all concordant.
Analysis of the expression level of VEGFA and VEGFR3
To further assess the correlations between mRNA expressions of VEGFA and VEGFR3 and the polymorphisms of rs2010963 and rs448012 in vivo, 53 normal renal tissues containing 100% normal cells obtained adjacent to tumour from patients with different genotypes were collected to perform real-time reverse transcription PCR (qRT-PCR). Total RNA was extracted from these samples using Trizol Reagent (Invitrogen, Carlsbad, CA) in accordance with the manufacturer's protocol. All samples were reverse transcribed and then measured using real-time quantitative RT-PCR using a 7900HT Real-Time PCR system (Applied Biosystems). The reaction was performed under the following conditions: 95°C for 10 min and 40 cycles of 95°C for 15 s and 60°C for 60 s. β-Actin was used as a quantitative control and the relative expression levels relative to β-actin were calculated using the 2 −∆ct method. Each reaction was performed in triplicate.
Construction of luciferase reporter plasmids and luciferase reporter gene assays
For further functional analysis of VEGFA rs2010963, which is located in the promoter region, vectors containing the SNP were constructed according to manufacturer's instructions. The 90-bp fragments in the promoter region around rs2010963 were synthesised (Invitrogen), containing VEGFA rs2010963C allele and VEGFA rs2010963G allele. The fragments were cloned respectively into pGL3-promoter vectors via the restriction sites MluI/XhoI. Each plasmid was confirmed through DNA sequencing.
The human cell lines HK-2, HEK-293T and HeLa were purchased from the Cell Bank Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Cells of the cell lines 293-T, HK-2 or HeLa were seeded onto 24-well culture plates. After 24 h, each well was co-transfected with Lipofectamine 2000 (Invitrogen) with 800 ng of the constructed luciferase vectors and 0.8 ng pRL-SV40 containing Renilla luciferase gene, which was used as an internal standard. Additionally, the empty pGL3-promoter vector was used as a negative control for every cell line. Cells were collected 48 h after transfection and lysed with Passive Lysis Buffer (Promega). The luciferase activities were measured via the Dual-Luciferase Reporter Assay System (Promega) in accordance with the manufacturer's instructions and calculated relative to Renilla's activities. Transfections were conducted in independent experiments in triplicate.
Statistical analyses
All of the statistical analyses in the present study were performed using SAS 9.1.3 software (SAS Institute, Cary, NC). Differences in the distributions of demographic characteristics, selected variables and frequencies of the genotypes of these SNPs were evaluated by Student's t-test for continuous variables and the chi-square test for categorical variables. The Hardy-Weinberg equilibrium of the genotype distribution among the controls was tested by a goodness-of-fit chi-square test. Unconditional logistic regression analyses were conducted to calculate the crude and adjusted odds ratios (ORs) and their 95% confidence intervals (CIs) for the risk of ccRCC. Additionally, the false discovery rate (FDR) was used to adjust the P value for multiple comparisons, based on the Benjamini-Hochberg method. The associations were considered statistically significant when Bonferroni FDR-adjusted P values were <0.05. The 2 −∆ct method was used to evaluate the relative expression levels of VEGFA and VEGFR3 in all samples, relative to those of U6. The unpaired Student's t-test was used to explore associations between the two polymorphisms (rs2010963 and rs448012) and the mRNA levels of VEGFA and VEGFR3 and dual-luciferase reporter gene expressions. All statistical tests were two sided and P < 0.05 was considered statistically significant.
Results
Characteristics and clinical features of all subjects
In this study, cases and controls were matched in age (P = 0.774), gender (P = 0.102) and drinking status (P = 0.113; Table I ). However, there were more smokers, obese subjects, hypertension patients and diabetic patients in the ccRCC group than in the control group (P = 0.001, 0.007, <0.001 and <0.001, respectively). Of the 859 ccRCC patients, the prevalences of clinical stages I, II, III and IV were 577 (67.2%), 170 (19.8%), 57 (6.7%) and 55 (6.4%), respectively, and those of nuclear grades I, II, III and IV were 176 (20.5%), 470 (54.7%), 171 (19.9%) and 42 (4.9%).
Associations between polymorphisms in angiogenesisrelated genes and the risk of ccRCC
Except for rs10434, rs1870377, rs2305948, rs59769082 and rs2229562, the remaining 19 tag-SNPs all conformed to Hardy-Weinberg equilibrium (Table II) . Five polymorphisms were significantly associated with ccRCC: VEGFA rs2010963, VEGFR1 rs3812867, VEGFR3 rs1382302, VEGFR3 rs448012 and VEGFR3 rs1049095. However, after adjusting for multiple comparisons, the associations remained for only two tag-SNPs (VEGFA rs2010963 and VEGFR3 rs448012; FDR = 0.048 for both rs2010963 and rs448012).
As shown in Table III , in VEGFA rs2010963 (G>C), which was located in the promoter region, subjects with GC and CC genotypes had significantly increased risk of ccRCC compared with those with GG (GC cf. GG: adjusted OR = 1.36, 95% CI = 1.10-1.68; CC cf. GG: adjusted OR = 1.37, 95% CI = 1.03-1.82). When subjects with GC and CC genotypes were combined, the combined group was also associated with a significantly increased risk of ccRCC (adjusted OR = 1.36, 95% CI = 1.12-1.66).
Another tag-SNP was VEGFR3 rs448012 (G>C), which is located in the exon region of VEGFR3. Compared with the homozygous GG genotype, subjects carrying GC or CC genotypes had a significantly increased susceptibility to ccRCC (GC cf. GG: adjusted OR = 1.29, 95% CI = 1.04-1.60; CC cf. GG: adjusted OR = 1.64, 95% CI = 1.24-2.17). The combined analyses were consistent with the above results (CC cf. GG + GC: adjusted OR = 1.43, 95% CI = 1.11-1.84; CC + GC cf. GG: adjusted OR = 1.38, 95% CI = 1.13-1.69).
Associations between VEGFA rs2010963 and VEGFR3 rs448012 and the expression levels of corresponding mRNA
We assessed the associations between these two polymorphisms and the expression of corresponding genes in 53 normal tissues adjacent to tumours using quantitative real-time RT-PCR. According to the results for the genotypes, the frequency distributions of CC, CG and GG were 8, 18 and 27 in rs2010963, respectively, and 10, 21 and 22 in rs448012. Samples of patients with VEGFA rs2010963 CC + CG genotypes had higher expression levels of VEGFA mRNA (P = 0.036) than did samples with GG genotypes (Figure 1 ). However, in rs448012, the mRNA levels of the CC + CG and GG genotypes were similar (P = 0.478).
Associations between rs2010963 and the clinicopathological characteristics of ccRCC patients
A stratification analysis was performed based on the clinicopathological characteristics of ccRCC patients (Table IV) . The association appeared to be significantly stronger in subjects with localised clinical stages (OR = 1.45, 95% CI = 1.18-1.79) and well-differentiated nuclear grades (OR = 1.40, 95% CI = 1.13-1.73). However, in subjects with advanced stage and moderately or poorly differentiated nuclear grade, no significant difference was observed.
Functional results of VEGFA rs2010963 via luciferase reporter gene assays
Based on the bioinformatics analysis from the dbSNP website in National Center of Biotechnology Information (http://www.ncbi.nlm.nih.gov/pubmed) and the software of TFSEARCH (http://www.cbrc.jp/research/db/TFSEARCH. html), VEGFA rs2010963 is involved in a predicted binding site for the transcription factor StuAp. We tested whether this polymorphism is functionally significant by altering the VEGFA promoter activity. The empty vectors were transfected into 293-T, HeLa and HK-2 cells as negative control. As shown in Figure 2 , plasmids containing the rs2010963 C allele had higher luciferase activities compared with the plasmids containing the rs2010963 G allele (P values for three cell lines were all ≤0.05). These results suggest that the rs2010963 C allele in the promoter region increased the transcriptional activity of VEGFA.
Discussion
In the present study, 24 SNPs among seven genes (HIF1A, EPAS1, VEGFA, VEGFR1, VEGFR2, VEGFR3 and PDGFRB) were selected, which have been associated with angiogenesis in tumours. In these 24 SNPs, rs10434, rs1870377, rs2305948, Fig. 1 . Samples with VEGFA rs2010963 CC + CG genotypes were associated with higher expression levels of VEGFA mRNA (P = 0.036) compared with samples with GG genotypes in normal tissues of ccRCC patients. However, in rs448012, there was no difference in mRNA levels between the CC + CG and GG genotypes (P = 0.478). rs59769082 and rs2229562 were excluded because they did not conform to the Hardy-Weinberg equilibrium. One probable explanation was that this was hospital-based research and some selective bias of these five SNPs did exist. We found that in VEGFA rs2010963 (G>C) and VEGFR3 rs448012 (G>C), located in the promoter and exon regions, respectively, subjects with GC and CC genotypes had significantly increased risk of ccRCC compared with those with the GG genotype. Our results in kidney cancer are similar to those of some other researchers in various cancers (13, 14) . However, Kawai et al. (15) and Sáenz-López et al. (16) found no association between VEGFA rs2010963 (G>C) and RCC, although we should note that the sample sizes of both were relatively small and the histopathology was mixed. Additionally, Adjusted for age, gender, body mass index, smoking status, drinking status, hypertension and diabetes in a logistic regression model.
Fig. 2.
Plasmids containing the rs2010963 C allele showed higher luciferase activities compared with plasmids containing the rs2010963 G allele. These results suggest that the rs2010963 C allele in the promoter region was more transcriptionally active with regard to VEGFA. *P < 0.05 for rs2010963 C vs. rs2010963 G allele in three cell lines.
we observed that the VEGFA rs2010963 CC + CG was associated with the increased risk of ccRCC in subgroups of localised clinical stage and well-differentiated nuclear grade. We hypothesised that advanced stage or poor-differentiated grade ccRCCs might have some genetic interaction with VEGFA rs2010963 or some gene-gene interactions might be more complicated in these conditions. However, it should be noted that the subject sizes of advanced clinical stage and poor-differentiated nuclear grade ccRCCs were too small, and further studies should be performed to recruit more patients. As we know, the majority of RCC is clear cell carcinoma, and the hereditary and sporadic forms of ccRCC are characterised by mutations in VHL (17) . VHL is a tumour suppressor gene and can interact with HIFs, which regulate the transcription of downstream genes such as VEGFA. When cells are hypoxic, this complex interaction is disrupted, resulting in increased transcription of downstream genes, including VEGFA (18) . Hence, VEGFA has a potentially crucial role in promoting the development of ccRCC. Several researches have shown that VEGFA rs2010963 CC genotypes were correlated with higher levels of VEGFA production (19, 20) . Therefore, through using quantitative real-time RT-PCR, we found that samples with VEGFA rs2010963 CC + CG genotypes had higher expression levels of VEGFA mRNA (P = 0.036) compared with samples with GG genotypes. This indicated that subjects with the C allele have higher VEGFA levels and are at increased risk of ccRCC. However, in polymorphism of VEGFR3 rs448012 (G>C), there was no difference in the mRNA levels between the CC + CG and GG genotypes.
Based on the bioinformatics analysis, the polymorphism of rs2010963 lies in a predicted binding site of StuAP (a transcription factor) in the promoter of VEGFA. And the polymorphism of C to G was predicted to lose the StuAP binding site. So, we hypothesised that this mutation might influence the promoter activity. In this study, the results of luciferase reporter gene assays showed that plasmids containing the rs2010963 C allele had a higher luciferase activity than plasmids containing the rs2010963 G allele. Combining with the results of RT-PCR, we suggest that the rs2010963 C allele in the promoter region resulted in increased transcriptional activity of VEGFA.
Currently, some VEGFA inhibitors such as sorafenib and sunitinib have been applied in RCC clinical treatments, and the preliminary data are encouraging (21, 22) . If the VEGFA genotype can be used to predict patients' angiogenic potential, the efficacy of antiangiogenic treatment in RCC patients would be further enhanced.
There are some limitations in our present study. We did not test the VEGFA levels in tumour tissues, and we also did not examine the serum VEGFA levels in RCC patients. All the selected polymorphisms were analyzed on genomic, not tumour; it is possible that the specific production of VEGFA cannot reflect the germline variation in VEGFA gene.
In conclusion, our study indicates that the functional polymorphism in VEGFA (rs2010963 G>C) is associated with risk of ccRCC, possibly due to altered VEGFA expression. This suggests that the VEGFA rs2010963 (G>C) polymorphism could be a marker of genetic susceptibility to ccRCC. These findings may help the identification of at-risk populations for primary cancer prevention. To explore the exact biological mechanism of VEGFA rs2010963 (G>C) genotypes and their interaction with other tumourigenic factors, further functional research with a larger sample size are warranted.
